{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:23Z","timestamp":1786980143569,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007041","name":"Universidad de Zaragoza","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007041","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In relapsing\u2013remitting multiple sclerosis (RRMS), conventional immunomodulatory and immunosuppressive therapies are widely used. However, in many cases, optimal control of inflammatory activity and disease progression is not achieved, which has led to the use of biological drugs such as monoclonal antibodies that act specifically on key components of the immune system. The aim was to evaluate the efficacy and safety of monoclonal antibodies compared to other drugs or placebo in adult patients with RRMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was performed based on randomized, double-blind, phase III controlled clinical trials published between 2012 and 2025 in the PubMed, Cochrane Library, and Web of Science databases, assessing efficacy and safety in adult patients with RRMS. The review was carried out following the PICO methodology and PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11 studies were included, evaluating 5 monoclonal antibodies: alemtuzumab, daclizumab, ocrelizumab, ofatumumab, and ublituximab. These therapies showed superior efficacy compared to conventional treatments in reducing the annual relapse rate, MRI inflammatory activity and MRI activity, particularly in patients with highly active disease. However, effects on disability progression were heterogeneous across trials and not consistently significant. In addition, decreases in biomarkers of axonal damage were observed. Nevertheless, relevant adverse effects were identified, including infections, autoimmune reactions, hepatic and cutaneous toxicity, whose incidence varies depending on the drug, requiring close clinical monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Monoclonal antibodies are an effective option in RRMS, with clinical and radiological benefits superior to those of conventional treatments. Their use requires individualized assessment and close follow-up due to the risk of adverse effects, especially in high-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13824-y","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:52:29Z","timestamp":1776851549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-0417","authenticated-orcid":false,"given":"Ana","family":"Avedillo-Salas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Baeza","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fanlo-Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Vicente-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"1","key":"13824_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple Sclerosis. Nat Rev Dis Primers 4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"13824_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014) Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology 83(11):1022\u20131024. https:\/\/doi.org\/10.1212\/WNL.0000000000000768","journal-title":"Neurology"},{"key":"13824_CR3","unstructured":"MS Society of Canada (2018) What is MS? Available at: https:\/\/mscanada.ca\/intro-to-ms\/what-is-multiple-sclerosis"},{"issue":"3","key":"13824_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1212\/CON.0000000000000728","volume":"25","author":"AJ Solomon","year":"2019","unstructured":"Solomon AJ (2019) Diagnosis, differential diagnosis, and misdiagnosis of Multiple Sclerosis. Continuum (Minneap Minn) 25(3):611\u2013635. https:\/\/doi.org\/10.1212\/CON.0000000000000728","journal-title":"Continuum (Minneap Minn)"},{"issue":"8","key":"13824_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1474-4422(23)00148-5","volume":"22","author":"AJ Solomon","year":"2023","unstructured":"Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W 3rd, Waubant EL, Yamout B, Cohen JA (2023) Differential diagnosis of suspected Multiple Sclerosis: an updated consensus approach. Lancet Neurol 22(8):750\u2013768. https:\/\/doi.org\/10.1016\/S1474-4422(23)00148-5","journal-title":"Lancet Neurol"},{"issue":"78","key":"13824_CR6","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1016\/j.med.2023.04.010","volume":"13","author":"M Alberte-Woodward","year":"2023","unstructured":"Alberte-Woodward M, Naveiro Soneira J, Prieto Gonz\u00e1lez JMO (2023) Actualizaci\u00f3n en esclerosis m\u00faltiple: manifestaciones cl\u00ednicas, formas evolutivas y estudios paracl\u00ednicos. Medicine 13(78):4621\u20134627. https:\/\/doi.org\/10.1016\/j.med.2023.04.010","journal-title":"Medicine"},{"key":"13824_CR7","unstructured":"The Multiple Sclerosis International Federation (MSIF). (2020) Atlas of MS, 3rd Edition. Part 1: Mapping multiple sclerosis around the world, key epidemiology findings. Available at: https:\/\/www.msif.org\/wp-content\/uploads\/2020\/12\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf"},{"issue":"2","key":"13824_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of Multiple Sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"13824_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O\u2019Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, St\u00fcve O, Waubant E, Polman CH (2014) Defining the clinical course of Multiple Sclerosis: the 2013 revisions. Neurology 83(3):278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"13824_CR10","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda. Manual de pr\u00e1ctica cl\u00ednica en Esclerosis M\u00faltiple, NMO y MOGAD (2023). [citado 23 de mayo de 2025]. Available at: https:\/\/www.sen.es\/pdf\/2023\/GuiaEsclerosis_2023web.pdf"},{"issue":"3","key":"13824_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1191\/1352458502ms804oa","volume":"8","author":"LG Palacio","year":"2002","unstructured":"Palacio LG, Rivera D, Builes JJ, Jim\u00e9nez ME, Salgar M, Anaya JM, Jim\u00e9nez I, Camargo M, Arcos-Burgos M, S\u00e1nchez JL (2002) Multiple Sclerosis in the tropics: genetic association to STR\u2019s loci spanning the HLA and TNF. Mult Scler 8(3):249\u2013255. https:\/\/doi.org\/10.1191\/1352458502ms804oa","journal-title":"Mult Scler"},{"issue":"8","key":"13824_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA (2024) Review of Multiple Sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore) 103(8):e37297. https:\/\/doi.org\/10.1097\/MD.0000000000037297","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"13824_CR13","doi-asserted-by":"publisher","first-page":"T155","DOI":"10.1016\/j.farma.2023.05.005","volume":"47","author":"AS P\u00e9rez","year":"2023","unstructured":"P\u00e9rez AS, Casado SE, Payero M\u00c1, Pueyo \u00c1E, Bernab\u00e9 \u00c1GA, Zamora NP, Ruiz PD, Gonz\u00e1lez AML (2023) Disease-modifying treatments for patients with Multiple Sclerosis in Spain. Farm Hosp 47(4):T155\u2013T160. https:\/\/doi.org\/10.1016\/j.farma.2023.05.005","journal-title":"Farm Hosp"},{"issue":"4","key":"13824_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31128\/AJGP-07-21-6103","volume":"51","author":"BS Travers","year":"2022","unstructured":"Travers BS, Tsang BK, Barton JL (2022) Multiple sclerosis: diagnosis, disease-modifying therapy and prognosis. Aust J Gen Pract 51(4):199\u2013206. https:\/\/doi.org\/10.31128\/AJGP-07-21-6103","journal-title":"Aust J Gen Pract"},{"issue":"10","key":"13824_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","volume":"18","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N (2019) Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol 18(10):973\u2013980. https:\/\/doi.org\/10.1016\/S1474-4422(19)30151-6","journal-title":"Lancet Neurol"},{"key":"13824_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"13824_CR17","unstructured":"Ryan R, Hill S (2016). How to GRADE the Quality of the Evidence. Cochrane Consumers and Communication Group. CCCG. Version 3.0 December 2016. http:\/\/cccrg.cochrane.org\/author-resources"},{"key":"13824_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"9856","key":"13824_CR19","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"4","key":"13824_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/13524585211032348","volume":"28","author":"J Kuhle","year":"2022","unstructured":"Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, R\u04e7sch N, Kaiser C, Mitchell CP, Leppert D, Havari E, Kappos L (2022) Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler 28(4):573\u2013582. https:\/\/doi.org\/10.1177\/13524585211032348","journal-title":"Mult Scler"},{"issue":"19","key":"13824_CR21","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","volume":"87","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA, CARE-MS II Investigators (2016) Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology 87(19):1985\u20131992. https:\/\/doi.org\/10.1212\/WNL.0000000000003319","journal-title":"Neurology"},{"issue":"15","key":"13824_CR22","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O\u2019Neill G, Elkins J (2015) Daclizumab HYP versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 373(15):1418\u20131428. https:\/\/doi.org\/10.1056\/NEJMoa1501481","journal-title":"N Engl J Med"},{"issue":"6","key":"13824_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1352458517707345","volume":"24","author":"RH Benedict","year":"2018","unstructured":"Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G (2018) Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: results from the DECIDE study. Mult Scler 24(6):795\u2013804. https:\/\/doi.org\/10.1177\/1352458517707345","journal-title":"Mult Scler"},{"issue":"7","key":"13824_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s12325-016-0353-2","volume":"33","author":"JG Krueger","year":"2016","unstructured":"Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J (2016) Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon Beta-1a in relapsing-remitting multiple sclerosis. Adv Ther 33(7):1231\u20131245. https:\/\/doi.org\/10.1007\/s12325-016-0353-2","journal-title":"Adv Ther"},{"issue":"3","key":"13824_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"9","key":"13824_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132\u20131140. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568","journal-title":"JAMA Neurol"},{"issue":"6","key":"13824_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, H\u00e4ring DA, Ramanathan K, Merschhemke M, Kappos L, ASCLEPIOS I and ASCLEPIOS II Trial Groups (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383(6):546\u2013557. https:\/\/doi.org\/10.1056\/NEJMoa1917246","journal-title":"N Engl J Med"},{"issue":"10","key":"13824_CR28","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/13524585221078825","volume":"28","author":"J G\u00e4rtner","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, H\u00e4ring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L (2022) Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler 28(10):1562\u20131575. https:\/\/doi.org\/10.1177\/13524585221078825","journal-title":"Mult Scler"},{"issue":"8","key":"13824_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC, ULTIMATE I and ULTIMATE II Investigators (2022) Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 387(8):704\u2013714. https:\/\/doi.org\/10.1056\/NEJMoa2201904","journal-title":"N Engl J Med"},{"key":"13824_CR30","volume-title":"Alemtuzumab (Lemtrada\u00ae): restricciones de uso provisionales por motivos de seguridad. Nota informativa MUH (FV), n\u00ba 6\/2019","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS)","year":"2019","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) (2019) Alemtuzumab (Lemtrada\u00ae): restricciones de uso provisionales por motivos de seguridad. Nota informativa MUH (FV), n\u00ba 6\/2019. AEMPS, Madrid"},{"key":"13824_CR31","unstructured":"European Medicines Agency (EMA). Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada (alemtuzumab). EMA\/609015\/2019. Amsterdam: EMA; 2019 Nov 15 [cited 2026 Feb 13]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis-medicine-lemtrada_en.pdf"},{"key":"13824_CR32","unstructured":"European Medicines Agency (EMA). Zinbryta (daclizumab beta) suspended and withdrawn in the EU following safety review. EMA\/286850\/2018. Amsterdam: EMA; 2018 Mar 18 [cited 2026 Feb 13]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/zinbryta-article-20-procedure-ema-review-zinbryta-confirms-medicines-risks-outweigh-its-benefits_en.pdf"},{"issue":"8","key":"13824_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.33588\/rn.6608.2018083","volume":"66","author":"FC Perez-Miralles","year":"2018","unstructured":"Perez-Miralles FC (2018) Daclizumab in multiple sclerosis. Rev Neurol 66(8):271\u2013282","journal-title":"Rev Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13824-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13824-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13824-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:44:20Z","timestamp":1779446660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13824-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13824"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13824-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"286"}}